Legcolax powder for oral solution 4 g. sackets №10


Manufacturer: Ukraine

Symptomatic treatment of constipation.



Legcolax Storage

active substance: macrogol;

1 sachet contains polyethylene glycol (macrogol) 4000 in terms of 100% substance 4 g or 10 g

Dosage form. Powder for oral solution.

Main physical and chemical properties: white or almost white powder.

Pharmacotherapeutic group. Laxatives. Osmotic laxatives. Macrogol. ATX code A06A D15.

Legcolax Pharmacological properties.

Pharmacodynamics. Due to the formation of hydrogen bonds with water molecules, the drug retains it in the intestine. This increases the fluid content in the intestinal cavity, which improves the process of defecation.

Pharmacokinetics. The laxative effect of the drug occurs 24-48 hours after ingestion.

The drug is not absorbed or metabolized. Excreted unchanged.

Legcolax Clinical characteristics.


Symptomatic treatment of constipation.

Legcolax Contraindication.

Hypersensitivity to macrogol.

Inflammatory diseases of the colon (nonspecific ulcerative colitis, Crohn’s disease, toxic megacolon).

Intestinal obstruction or suspected intestinal obstruction.

Perforation of the gastrointestinal tract or its threat.

Abdominal pain of unknown origin.

Interaction with other medicinal products and other forms of interaction.

There may be a delay in the absorption of drugs taken concomitantly with Legcolax. Therefore, it is recommended to take the drug separately from other drugs, with an interval of at least 2 hours.

Features of application.

Prior to treatment, the organic nature of constipation should be ruled out. Treatment of constipation with any drug is only an adjunct therapy provided a healthy lifestyle and diet, namely: consumption of more fluids and fiber, appropriate physical activity and recovery of intestinal function.

The maximum duration of use for children – no more than 3 months.

The fact that symptoms do not disappear even as a result of drug use and adherence to a proper diet may indicate other pathologies that need diagnosis and treatment.

Cases of aspiration with large volumes of polyethylene glycol electrolytes through a nasogastric tube have been reported. A special risk of aspiration is observed in children with neurological disorders of swallowing.

It should be used with caution in patients prone to water-electrolyte imbalance, namely: elderly patients, patients with impaired liver or kidney function; with concomitant use of diuretics, given the possibility of diarrhea. It is also recommended to monitor the electrolyte balance.

The drug does not contain sugar, so it can be prescribed to patients with diabetes, as well as persons whose diet excludes galactose.

Because the drug contains macrogol, there may be symptoms of hypersensitivity to the active substance (see section “Adverse reactions”).

Use during pregnancy or breastfeeding.

The drug can be prescribed during pregnancy or breastfeeding.

Ability to influence the speed of reaction when driving a car or other machinery.

Not installed.

Method of application and dosage.

The drug is intended for oral administration.

Treatment normalizes the motility of the large intestine, provided that the appropriate culture of nutrition (diet).

Adults and children over the age of 8 are usually prescribed 10-20 g per day.

The daily dose for children from 6 months to 1 year is 4 g, from 1 year to 4 years – 8 g, from 4 to 8 years – 16 g.

The contents of the sachet are pre-dissolved in a glass of water, clear juice (eg, apple) or iced tea, children under 1 year – in 50 ml of water.

Take Legcolax preferably in the morning with a meal, in one sitting.

The first effect of the drug occurs within 24-48 hours after ingestion.

The daily dose is determined according to the clinical effect and can range from 4 g every other day (for children) to 20 g per day.

The duration of use is determined by the doctor depending on the nature and course of the disease, the effectiveness of treatment. The duration of treatment for children should not exceed 3 months, as there are no clinical studies on the use of the drug beyond this period.


The drug can be used in children over 6 months of age.